Atorvastatin Reduces Plaque Vulnerability in an Atherosclerotic Rabbit Model by Altering the 5-Lipoxygenase Pathway

@article{Zhou2010AtorvastatinRP,
  title={Atorvastatin Reduces Plaque Vulnerability in an Atherosclerotic Rabbit Model by Altering the 5-Lipoxygenase Pathway},
  author={Guangyi Zhou and Song Ge and Dezhi Liu and Gelin Xu and Renliang Zhang and Qin Yin and Wusheng Zhu and Jieli Chen and Xinfeng Liu},
  journal={Cardiology},
  year={2010},
  volume={115},
  pages={221 - 228}
}
Objective: The 5-lipoxygenase catalyzed formation of leukotriene lipid mediators is a mediator for inflammatory response in arteries. The present study investigated the relationship between atorvastatin and the 5-lipoxygenase pathway in an atherosclerotic rabbit model. Methods: Thirty male New Zealand White Rabbits were randomized into negative control, positive control and atorvastatin groups. At week 4, the rabbits were subjected to carotid balloon-dilation injury or carotid balloon-dilation… Expand
Atorvastatin Inhibits the 5-Lipoxygenase Pathway and Expression of CCL3 to Alleviate Atherosclerotic Lesions in Atherosclerotic ApoE Knockout Mice
TLDR
It is suggested that atorvastatin significantly alleviated atherosclerotic lesions by inhibiting the 5-LO pathway and down regulating the expression of CCL3 in ApoE−/− mice. Expand
β-Elemene reduces the progression of atherosclerosis in rabbits.
TLDR
It is demonstrated that β-elemene retarded the progression of atherosclerosis in vivo and in vitro, which may be related to the capacity of β- elemene to reduce the infiltration of macrophages and suppress inflammatory factors. Expand
Effect of high-dose atorvastatin on advanced soft atherosclerotic plaque in rabbit carotid artery using ultrasonographic and histological methods
TLDR
The pleiotropic and lipophilic effects of high-dose atorvastatin accompanied by discontinuation of cholesterol-rich diet can cause to exterminate the microvessels, improve the fibro-lipid lesion in the soft plaque and significantly dilate the luminal cross-sectional area of stenosis. Expand
No effect of high-dose atorvastatin on leukotriene B₄ formation from neutrophils in patients treated with coronary bypass surgery: a randomized placebo-controlled double-blinded trial with a crossover design.
TLDR
There was no significant correlation between baseline LDL cholesterol levels on formation of LTB₄, and atorvastatin had no effect on LTB ₄ formation, so this study does not support any effect of atorVastatin on L TB₀ formation as part of the explanation for its beneficial effect on CVD. Expand
Berberine combined with atorvastatin downregulates LOX‑1 expression through the ET‑1 receptor in monocyte/macrophages.
TLDR
The results demonstrated that berberine combined with atorvastatin downregulates LOX‑1 expression through ET‑1 receptors in monocyte/macrophages in vitro and in vivo. Expand
Statins as regulators of redox state in the vascular endothelium: beyond lipid lowering.
TLDR
Better understanding of the mechanisms that underlie endothelial dysfunction could lead to the design of novel therapeutic strategies that target the vascular endothelium for the prevention and treatment of CVD. Expand
Atherosclerosis , inflammation and leukotrienes
Atherosclerosis, which is a chronic inflammatory disease that leads to the formation of plaque on the inner lining of the arteries, is a global problem in terms of its consequences such as myocardialExpand
Effects of 3,4-dihydroxyacetophenone on the hypercholesterolemia-induced atherosclerotic rabbits.
TLDR
3,4-DHAP may attenuate the progression of atherosclerotic lesions and stabilize plaques by lowering plasma lipids, the number of macrophages and the expression of VCAM-1, while increasing the number aortic plaque instability and VSMCs in the atherosclerosis plaques. Expand
Anti-inflammatory effects of trihoney in hypercholesterolemicatherosclerotic rabbits: a comparative study with atorvastatin
TLDR
It is shown that Trihoney has an anti-inflammatory function and may be used as an adjuvant to statins for management of atherosclerotic cardiovascular diseases even in diabetic subjects. Expand
Modulation of Eicosanoid Production and Activity as a Potential Explanation for Some of the Pleiotropic Effects of Statins
TLDR
The effects of mevalonic supplementation suggest that local inhibition of the enzyme in nonhepatic cells and tissues are responsible for these diverse effects of statins. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 42 REFERENCES
Anti-atherogenic effects of montelukast associated with reduced MCP-1 expression in a rabbit carotid balloon injury model.
TLDR
The results suggest that montelukast produces anti-atherogenic effects unrelated to plasma lipid modulation but related to MCP-1 down regulation. Expand
Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration.
TLDR
It is demonstrated that a direct effect of atorvastatin is demonstrated to inhibit the progression of aortic aneurysm, independent of its lipid-lowering effect. Expand
Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis
TLDR
The data support a model of atherogenesis in which 5-lipoxygenase cascade-dependent inflammatory circuits consisting of several leukocyte lineages and arterial wall cells evolve within the blood vessel wall during critical stages of lesion development, and raise the possibility that antileukotriene drugs may be an effective treatment regimen in late-stage disease. Expand
Association Between 5-Lipoxygenase Expression and Plaque Instability in Humans
TLDR
The expression of 5-LO is elevated in symptomatic compared with asymptomatic plaques and is associated with acute ischemic syndromes, possibly through the generation of LTB4, subsequent MMP biosynthesis, and plaque rupture. Expand
Atorvastatin inhibits angiotensin-converting enzyme induction in differentiating human macrophages.
TLDR
The finding that atorvastatin inhibited ACE upregulation may represent a novel pleiotropic action and an additional beneficial effect of statins in treatment of cardiovascular disease. Expand
5-Lipoxygenase–Activating Protein: A Potential Link Between Innate and Adaptive Immunity in Atherosclerosis and Adipose Tissue Inflammation
TLDR
The results of the present study suggest a key role for mediators of the 5-lipoxygenase pathway in inflammatory reactions of atherosclerosis and metabolic disease. Expand
The 5 lipoxygenase system in the vasculature: Emerging role in health and disease
TLDR
Genetic variants in the 5LO activating protein are strongly linked to increased cardiovascular risk and may serve as useful markers for future therapy targeting down regulation of 5LO expression and activity as a means to combat cardiovascular disease. Expand
Statins Reduce Inflammation in Atheroma of Nonhuman Primates Independent of Effects on Serum Cholesterol
TLDR
In primates, these results provide further support for the beneficial effect of statins on plaque inflammation and stability in addition to cholesterol lowering. Expand
Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome.
TLDR
Nuclear factor-kappa B activity in peripheral blood mononuclear cells, and plasma PGE2 levels and MMP-9 activity, increase during NSTEACS, providing additional mechanisms by which intensive atorvastatin therapy may reduce the incidence of cardiovascular events. Expand
Effects of Atorvastatin on the Different Phases of Atherogenesis
TLDR
The question of whether the clinical benefit of statins such as atorvastatin in reducing cardiovascular events in individuals with elevated cholesterol levels results from direct anti-atherogenic effects in addition to cholesterol-lowering-dependent effects cannot be conclusively answered at present. Expand
...
1
2
3
4
5
...